Prostate Cancer Therapy
Research in the area of prostate cancer therapy reported from University of California, San Francisco Comprehensive Cancer Center
Published in Drug Law Weekly, November 6th, 2007
New investigation results, 'A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer,' are detailed in a study published in BJU International. " To investigate, in a phase II trial, the use of the epidermal growth factor receptor (EGFR) inhibitor gefitinib as monotherapy in patients with non-metastatic hormone refractory prostate cancer (HRPC), as current treatment options for this disease are limited, and agents which target the EGFR should be assessed because EGFR is highly expressed in prostate cancer and associated with a poor prognosis. Patients with histologically or cytologically confirmed cancer of the prostate with no evidence of...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
Source: Drug Law Weekly (2007-11-06)
More Articles from Drug Law Weekly
- Alcoholism
Youth and Health Experts Call on the Governor to Take the Buzz Out of Energy Drinks - Bioengineering
IntelliPharmaCeuitics Ltd. Announces Generic Drug Commercialization Activities - Biopharmaceuticals
Protalix BioTherapeutics Announces Pricing of Public Offering of Common Stock - Biotechnology Business
Biovail Submits Complete Response to FDA for BVF-033 - Biotechnology Business
Celera Reports First Quarter Fiscal 2008 Results - Bird Flu
The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy - More from this issue of Drug Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
